The premise of therapeutic cancer vaccine is that tumor-reactive T cells (including CD8+ and CD4+ T cells) can be induced and expanded in patients by exposing the host immune system to tumor-associated antigens (TAAs). This evidence concerns the gene CD8A and neoplasm.